Our comprehensive pan-cancer analysis demonstrates that DDR1 is markedly overexpressed in diverse malignancies and is strongly associated with poor clinical outcomes, immunotherapy resistance, and diminished antitumor immune cell infiltration. This evidence concerns the gene DDR1 and cancer.